A5006173909- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Retinoids in leukemia and cellular processes
- T-cell and B-cell Immunology
- Neutropenia and Cancer Infections
- Multiple Myeloma Research and Treatments
- Immune Cell Function and Interaction
- Histone Deacetylase Inhibitors Research
- Immunodeficiency and Autoimmune Disorders
- Renal Transplantation Outcomes and Treatments
- Hematological disorders and diagnostics
- Blood disorders and treatments
- Childhood Cancer Survivors' Quality of Life
- Polyomavirus and related diseases
- Cancer Genomics and Diagnostics
- Viral-associated cancers and disorders
- Cytomegalovirus and herpesvirus research
- Antifungal resistance and susceptibility
- Pneumocystis jirovecii pneumonia detection and treatment
- Epigenetics and DNA Methylation
Hospital de Sant Pau
2013-2022
Universitat Autònoma de Barcelona
2012-2021
Josep Carreras Leukaemia Research Institute
2013-2021
Hudson Institute
2020
John Wiley & Sons (United States)
2020
Fundación Josep Carreras Contra la Leucemia
2019
Hospital Clínic de Barcelona
2017
Banc de Sang i Teixits
2013-2015
Institut Català d'Oncologia
2001-2014
Fundación Pethema
2004-2013
Background About one half of adults with acute lymphoblastic leukemia are not cured the disease and ultimately die. The objective this study was to explore factors influencing outcome adult patients relapsed leukemia.Design Methods We analyzed characteristics, prognostic for survival after first relapse in a series 263 (excluding those mature B-cell leukemia) prospectively enrolled four consecutive risk-adapted PETHEMA trials.Results median overall 4.5 months (95% CI, 4–5 months) 5-year 10%...
Purpose Patients with acute myeloid leukemia (AML) and FLT3/internal tandem duplication (FLT3/ITD) have poor prognosis if treated chemotherapy only. Whether this alteration also affects outcome after allogeneic hematopoietic stem-cell transplantation (HSCT) remains uncertain. Methods We analyzed 206 patients who underwent HLA-identical sibling matched unrelated HSCTs reported to the European Group for Blood Marrow Transplantation a diagnosis of AML normal cytogenetics data on FLT3/ITD...
Minimal residual disease (MRD) is an important prognostic factor in adults with acute lymphoblastic leukemia (ALL) and may be used for treatment decisions. The Programa Español de Tratamientos en Hematología (PETHEMA) ALL-AR-03 trial (Treatment of High Risk Adult Acute Lymphoblastic Leukemia [LAL-AR/2003]) assigned adolescent adult patients (age 15 to 60 years) high-risk ALL (HR-ALL) without the Philadelphia (Ph) chromosome chemotherapy or allogeneic hematopoietic stem-cell transplantation...
Summary. We have analysed the incidence and risk factors for occurrence of invasive fungal infections (IFI) among 395 recipients an allogeneic peripheral blood stem cell transplantation (PBSCT) from a human leucocyte antigen (HLA)‐identical sibling. IFI ( n = 50) occurred in 46 patients, giving overall probability 14%. There were 12 cases candidiasis (3%), with only one death. Non‐ Candida 37 patients (12% probability), mostly aspergillosis 32). In multivariate analysis two significant...
Data on 49 allogeneic bone marrow transplant (BMT) recipients who developed interstitial pneumonia due to cytomegalovirus (CMV) were collected retrospectively. All patients treated with ganciclovir and high doses of intravenous immune globulin, although types globulins schedules treatment varied. Seventeen (35%) responded treatment. Thirty days after the diagnosis pneumonia, survival rate among was 31%. CMV detected in 81% whom autopsies performed. The received total body irradiation (TBI)...
It has been recognized that cure is possible for human immunodeficiency virus (HIV)-infected patients with Burkitt lymphoma/leukemia (BL) if appropriate chemotherapy used. The introduction of rituximab in BL therapeutic schemes scarcely explored. outcome and toxicity HIV-positive treated a intensive chemotherapy-based trial was evaluated.Thirty-six consecutive patients, 15 to 55 years age, diagnosed advanced stage were recruited from July 2003 August 2006, stratified according HIV infection...
Background The prevalence of and risk factors for central nervous system recurrence in patients with acute promyelocytic leukemia are not well established remain a controversial matter.Design Methods Between 1996 2005, 739 newly diagnosed enrolled two consecutive trials (PETHEMA LPA96 LPA99) received induction therapy all-trans retinoic acid idarubicin. Consolidation comprised three courses anthracycline monochemotherapy (LPA96), reinforced doses idarubicin an intermediate or high relapse...
// Marina Díaz-Beyá 1, 2 , Salut Brunet 2, 3 Josep Nomdedéu 4 Marta Pratcorona Anna Cordeiro 5 David Gallardo 6 Lourdes Escoda 7 Mar Tormo 8 Inmaculada Heras 9 Maria Ribera 10 Rafael Duarte 11 María Paz Queipo de Llano 12 Joan Bargay 13 Antonia Sampol 14 Meritxell Nomdedeu 1 Ruth M. Risueño Montserrat Hoyos Jorge Sierra Mariano Monzo Alfons Navarro 5, * Jordi Esteve 15, on behalf of the Cooperative AML group CETLAM Hematology Department, Hospital Clinic,...
Summary The graft‐ versus ‐host disease (GVHD) characteristics of 150 consecutive patients undergoing reduced intensity conditioning allogeneic (allo‐RIC) transplants and 88 myeloablative regimen were analysed. All received the same GVHD prophylaxis peripheral blood stem cells from a human leucocyte antigen identical sibling. cumulative incidence acute (aGVHD) was 67% 44% in allo‐RIC groups, respectively ( P < 0·001), 39% vs. 29%, = 0·043), for grades 2–4 aGVHD. Only type (myeloablative...